Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated Jun 11, 2025, titled "Press Release on subscription of equity shares of Xbrane Biopharma AB, Sweden".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has announced a biosimilars manufacturing partnership with Sweden-based Xbrane Biopharma AB. As part of the deal, Xbrane will transfer the technology of select biosimilar products to OneSource's integrated Drug Substance and Drug Product facility in Bangalore. OneSource has also subscribed to equity shares in Xbrane through its latest funding round, aligning long-term interests. Xbrane's biosimilar portfolio targets EUR 23 billion in estimated annual peak sales, with its lead product Ximluci (a ranibizumab biosimilar) already approved in Europe and pending US launch. The partnership also helps OneSource fast-track regulatory approvals (US FDA and EMA) for its biologics drug substance facility.
This is a positive development for shareholders — it expands OneSource's order pipeline in the high-growth biosimilars CDMO segment, strengthens its global credibility, and the equity stake in Xbrane creates potential upside if Ximluci succeeds in the US market. The deal should support long-term revenue growth and improve utilization of its Bangalore biologics facility.